NCT04098887

Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma

A Phase I Trial of Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

Unresectable (including metastatic) conventional chondrosarcoma requires high dose radiation for local control. Radiation Oncologists have traditionally used long radiation courses and concern for toxicity to surrounding organs at risk. Stereotactic body radiation therapy (SBRT) has the ability to deliver high doses of radiation in a manner that may improve clinical response but has size limitations. SBRT delivered with lattice radiotherapy (LRT) may safely dose escalate smaller portions of the tumor and also provide improved cancer control. This study is to evaluate the safety and initial efficacy of this treatment approach.

Conditions

• Metastatic Chondrosarcoma

Interventions

Type	Name	Description
RADIATION	Lattice stereotactic body radiation therapy	For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV\_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV\_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV\_2000 and PTV\_6670, respectively).

Timeline

• Start date: 2020-10-31
• Primary completion: 2021-11-30
• Completion: 2021-11-30
• First posted: 2019-09-23
• Last updated: 2020-09-16

Regulatory

• FDA-regulated device study